The rescindment of the Richardson Waiver in late February suggests that the HHS may move toward rulemaking without providing public notice and comment procedures.
Latest News
How NIH, FDA Nominees May Affect Rheumatology
The nominations of Jay Bhattacharya, MD, PhD, as director of the National Institutes of Health and Martin Makary, MD, MPH, for commissioner of the Food & Drug Administration have the potential to significantly impact federally funded healthcare research, federal responses to public health emergencies and federal regulation of drugs and medical devices.
Flares Rare After COVID Vaccination
The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive…
2025 Advocates for Arthritis Applications Now Open
This annual event, to be held May 4–6, brings together the rheumatology community to advocate on Capitol Hill for the profession and rheumatic disease patients.
Will Telehealth Make It to April?
Medicare’s current telehealth flexibilities are set to expire March 31. To avoid a government shutdown, Congress must pass a appropriations package by midnight on March 14. The ACR is preparing for the impacts if a telehealth extension does not pass.
AI’s Expanding Role in Rheumatology & Healthcare
Disease detection, access to care and remote patient monitoring are just a few areas in which AI is expected to aid rheumatology, but there will still be room for the human touch.
